CLINICAL_TRIALS
trial_result
· 2018-03-20
Clinical Trial Update: CU Programme of Idarucizumab for Japanese Patients [Phase 3]
Summary
Phase 3 results for the idarucizumab program in Japanese patients with hemorrhage have been completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Hemorrhage | Phase 3 | Status: COMPLETED | Results posted: 2018-03-20